Antiphospholipid Antibodies: A New Risk Factor for Restenosis After Percutaneous Transluminal Coronary Angioplasty?

References

• Brenner B., Blumenfeld Z., Markiewicz W., Reisner S. A. Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol 1991; 4: 931–936
   Google Scholar
• Lechner K., Eichinger S., Jager U., Pabinger I., Kyrle P. A. Lupus anticoagulant and clinical correlates. Thrombosis: an update, G. G. Neri Serneri, et al. Scientific Press, Florence 1992; 47
   Google Scholar
• Nencini P., Baruffi M. C, Abbate R., Massai G., Amaducci L., Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992; 23: 29–32
   Google Scholar
• Brandt J. T., Triplett D. A., Alving B., Sharrer I. Criteria for diagnosis of lupus anticoagulant: an update. On behalf of the subcommittee on lupus anti-coagulant/antiphospholipid antibody of the Scientific and Standardization Committee of ISTH. Thromb Haemost 1995; 74: 1185–1190
   PubMed Web of Science ®Google Scholar
• Triplett D. A. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 1995; 78: 1–31
   PubMed Web of Science ®Google Scholar
• Libby P., Schwartz D., Brogi E., Tanaka H., Clinton S. K. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992; 86: 47–52
   PubMed Web of Science ®Google Scholar
• Savage M. P., Goldberg S., Bove A. A., Deutsch E., Vetrovec G., Macdonald R. G., Bass T., Margolis J. R., Withworth H. B., Taussig A., Hirshfeld J. W., Cowley M., Hill J. A., Marks R. G., Fishman D. L., Hand-Berg E., Herrmann H., Pepine J. P. Effect of Thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Circulation 1995; 92: 3200–3294
   Google Scholar
• Serruys P. N., Herrman J. P. R., Simon R., Rutschi W., Bode C., Laarman G. S., Vandijk R., Vandenbos A., Umans V. A. W.M., Fox K. A. A., Close P., Deckers J. W. A comparison of Hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333: 757–763, or the Helvetica Investigators.
   PubMed Web of Science ®Google Scholar
• Tcheng J. E., Harrington R. A., Kotthe-Marchant M., Klei-Man M. S., Ellis S. G., Kereiakes D. S., Mick M. J., Na-Vetta F. I., Smith S. E., Worley S. S., Miller S. A., Joseph D. M., Sigmon K. M., Kitt M. M., Du Mee C. P., Cauff R. M., Topol E. J. Multicenter, randomized double-blind placebo-controlled trial of the platelet integrin glicoprotein llb/llla blocker inte-grelin in elective coronary intervention. Circulation 1995; 91: 2151–2157, for the IMPACT investigators.
   PubMed Web of Science ®Google Scholar
• Huber K., Jorg M., Probst P., Schuster E., Lang L., Kaindl F., Binder B. R. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 1992; 67: 209–213
   PubMed Web of Science ®Google Scholar
• Sakata K., Miura F., Sugino H., Shinobe M., Shirotani M., Yoshida H., Mori N., Hoshino T., Takada A. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 1996; 131: 1–6
   PubMed Web of Science ®Google Scholar
• Piette J.-C. Diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: a mission impossible?. Lupus 1996; 5: 354–363
   PubMed Web of Science ®Google Scholar
• Dotter C. T., Judkins M. P. Transluminal treatment of arteriosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation 1964; 30: 654–70
   PubMed Web of Science ®Google Scholar
• DeGroote P., Bauters C., McFadden E., Lablanche J. M., Leroy F., Bertrand M. E. Local lesion-related factors and restenosis after coronary angioplasty. Circulation 1995; 91: 968–972
   PubMedGoogle Scholar
• Exner T., Triplett D. A., Taberner D., Machin S. J. Guidelines for testing and revised criteria for lupus anticoagulant. SSC subcommittee for the standardization of lupus anticoagulant. Thromb Haemost 1991; 65: 320–322
   PubMed Web of Science ®Google Scholar
• Lupus anticoagulant working party of BCSH. Haemo-stasis and thrombosis task force. Guidelines on testing for the lupus anticoagulant. J Clin Pathol 1991; 44: 885–889
   PubMedGoogle Scholar
• Alving B. M., Carr C. F., Johansen L. E., Tang D. B. Comparison between a onepoint dilute phospholipid aPTT and dilute Russel viper venom time for verification of lupus anticoagulants. Thromb Haemost 1992; 62: 672–678
   Google Scholar
• O'Neil A. L., Abrahaim K. M. A., Parkin J. D. Automation of the caolin clotting time. Pathology 1992; 24: 12–24
   PubMedGoogle Scholar
• Robert A. Two different incubation times for activated partial thromboplastin time (aPTT): a new criterion for diagnosis of lupus anticoagulant. Thromb Haemost 1994; 71: 220–224
   PubMedGoogle Scholar
• Triplett D. A., Brandt J. T., Kozacor D. Laboratory diagnosis of lupus inhibitor: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678–682
   PubMed Web of Science ®Google Scholar
• Harris E. N. Annotation: antiphospholipid antibodies. Br J Haematol 1990; 74: I–9
   Google Scholar
• Branch D. W., Silver R. M., Blackwell J. L., Reading J. C., Scott J. R. Outcome of treated pregnancies in women with antiphospholipid antibodies. Br J Haematol 1990; 74: 1–9
   Google Scholar
• Boddi M., Prisco D., Fedi S., Cellai A. P., Alessandrello Liotta A., Parretti E., Mecacci F., Mello G., Abbate R. Anthiphospholipid antibodies and pregnancy disorders in women with insulin dependent diabetes. Thromb Res 1996; 82: 207–216
   PubMedGoogle Scholar
• Pelzer H., Schwartz A., Stuber W. Determination of human prothrombin activation fragment 1 + 2 in plasma with antibodies against a synthetic peptide. Thromb Haemost 1991; 65: 153–159
   PubMed Web of Science ®Google Scholar
• Pelzer H., Schwartz A., Heimberg N. Determination of human thrombin-antithrombin complex in plasma with an enzyme linked immuno-sorbent assay. Thromb Haemost 1988; 59: 101–106
   PubMed Web of Science ®Google Scholar
• Elms M. J., Bunce I. H., Bundesen P. G., Rylatt D. B., Webber A. J., Masci P. P., Whitaker A. N. Measurement of cross-linked fibrin degradation products. An immuno-assay using monoclonal antibodies. Thromb Haemost 1983; 50: 591–597
   PubMed Web of Science ®Google Scholar
• Chmielewska J., Ranby H., Wiman D. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427–436
   PubMed Web of Science ®Google Scholar
• Vaarala O., Manttari M., Manninen V., Tenkanen L., Puu-Runen M., Aho K., Palosuo T. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle aged men. Circulation 1994; 91: 23–27
   Google Scholar
• Zukerman E., Toubi E., Shiran A., Sabo E., Shmuel Z., Dov Golan T., Abinader E., Yeshurun D. Anticardiolipin antibodies and acute myocardial infarction in nonsystemic lupus erythematosus patients: a controlled prospective study. Am J Med 1996; 171: 381–386
   Google Scholar
• Hamsten A., Norberg R., Bjorkholm M., De Faire U., Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1: 113–116
   PubMed Web of Science ®Google Scholar
• Klemp P., Cooper R. C, Strauss F. J., Jordan E. R., Przy-Bojewski J. Z., Nel N. Anticardiolipin antibodies in ischaemic heart disease. Clin Exp Immunol 1988; 74: 254–257
   PubMed Web of Science ®Google Scholar
• Hendra T. J., Baguley E., Harris E. N. Anticardiolipin antibodies levels in diabetic subjects with and without coronary artery disease. Postgrad Med J 1989; 65: 140–3
   PubMed Web of Science ®Google Scholar
• The antiphospholipid antibodies in stroke study group (APASS). Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke 1990; 21: 1268–1273
   PubMedGoogle Scholar
• Neri Serneri G. G., Abbate R., Gori A. M., Attanasio M., Martini F., Giusti B., Dabizzi R. P., Poggesi L., Mod-Esti P. A., Trotta F., Rostagno C., Boddi M., Gensini G. F. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation 1992; 86: 790–797
   PubMed Web of Science ®Google Scholar
• Liuzzo G., Biasucci L. M., Gallimore J. R., Grillo R. I., Rebuzzi A. G., Pepys S. M. B., Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 33: 414–424
   Google Scholar
• Neri Serneri G. G., Prisco D., Martini F., Gori A. M., Brunelli T., Poggesi L., Rostagno C., Gensini G. F., Abbate R. An acute T cell activation is detectable in unstable angina. Circulation 1997; 95: 1806–1812
   PubMed Web of Science ®Google Scholar
• Bittl J. A. Advances in coronary angioplasty. N Engl J Med 1996; 335: 1290–1302
   PubMed Web of Science ®Google Scholar
• Eber B., Schumaker M., Auer-Grumbach P., Toplac H., Klein W. Increased IgM-anticardiolipin antibodies in patients with restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992; 69: 1255–1258
   PubMedGoogle Scholar
• Morton K. E., Krilis A. S., Baron D. W., Gavaghan T. P., Daggard G. E., Hickie J. B., Chesterman C. N. Coronary artery By-Pass graft failure-an autoimmune phenomenon?. Lancet 1986; 2: 1353–1358
   PubMed Web of Science ®Google Scholar